Web Results

supreme.justia.com/cases/federal/us/562/223

BRUESEWITZ et al. v. WYETH LLC, fka WYETH, INC., et al. certiorari to the united states court of appeals for the third circuit. No. 09–152. Argued October 12, 2010—Decided February 22, 2011. The National Childhood Vaccine Injury Act of 1986 (NCVIA or Act) created a no-fault compensation program to stabilize a vaccine ...

www.druganddevicelawblog.com

This publication offers insight and commentary regarding the defense of pharmaceutical and medical device product liability litigation.

www.gordonrees.com/Templates/media/files/pdf/Scott%20v%20Ford%20Motor.pdf

Mar 26, 2014 ... (Conte v. Wyeth, Inc. (2008). 168 Cal.App.4th 89, 112.) The sole case cited by Ford finding that an absent warning was not a proximate cause of injury, however , was based on the impracticality of effectively communicating a warning, not on the plaintiff's likely resistance to it. (Huitt v. Southern California Gas ...

biotech.law.lsu.edu/cases/vaccines/reyes_v_wyeth_laboratories.htm

See Davis v. Wyeth Laboratories, Inc., 9 Cir. 1968, 399 F.2d 121, 129. [31], Wyeth does not deny that its vaccine is "unavoidably unsafe", or contend that it was ..... [ 69], Scott v. Fancher, 5 Cir. 1966, 369 F.2d 842, 844. It is at least arguable that the effect of a disease virus on a particular human being whom he had not ...

www.nam.org/Advocacy/The-Center-for-Legal-Action/Briefs-Online/2017/NAM-Amicus-Brief-in-Rafferty-v-Merck-and-Co-(Mass-S-Ct)

Aug 25, 2017 ... Wyeth,. No. CIV.A.MICV200303314B, 2005 WL 4056740. (Mass. Super. Ct. May 6, 2005) ................27, 36. Lashley v. Pfizer, Inc.,. 750 F.3d 470 (5th Cir. ...... See, e.g., Scott v. Elsevier Inc., No. 11-04445, slip op. at 5 (Mass. Super. Ct. Aug. 11, 2014). 4:11-CV-325 JAR, 2013 WL 3929059, at *20–23 (E.D. Mo.

www.justice.gov/opa/pr/wyeth-pharmaceuticals-agrees-pay-4909-million-marketing-prescription-drug-rapamune-unapproved

Jul 30, 2013 ... Wyeth Pharmaceuticals Inc., a pharmaceutical company acquired by Pfizer, Inc. in 2009, has agreed to pay $490.9 million to resolve its criminal and civil liability arising from the unlawful ... The first action was filed by a former Rapamune sales representative, Marlene Sandler, and a pharmacist, Scott Paris.

www.law.uh.edu/healthlaw/perspectives/2009/(BP)%20wyeth.pdf

Mar 4, 2009 ... Authority to Regulate the Specifics of Prescription Drug Labeling and the Preemption Debate, 61 FOOD &. DRUG L. J. 585 (2006). 3 The other two cases are Warner-Lambert v. Kent 552 U.S.___(2008) and Riegel v. Medtronic, Inc., 552. U.S.___(2008). 4 Wyeth, supra note 1. 5 Wyeth, supra note 1. 6. Rep.

www.courtswv.gov/supreme-court/docs/fall2010/35296.htm

McFoy v. Amerigas, Inc. 170 W. Va. 526, 295 S.E.2d 16 (1982); State ex rel. McGraw v. Scott-Runyan Pontiac-Buick, Inc., 194 W. Va. 770, 461 S.E.2d 516 ( 1995). With specific regard to the statutory private cause of action we have said that the WVCCPA was intended “to protect consumers from unfair, illegal, and deceptive ...

www.law360.com/articles/461203/wyeth-paying-491m-to-end-criminal-civil-rapamune-cases

Jul 30, 2013 ... Wyeth Pharmaceuticals Inc. has agreed to shell out $491 million to end a criminal action as well as civil False Claims Act cases alleging it illegally ... Claims Act by former Rapamune sales representative Marlene Sandler and pharmacist Scott Paris in 2005 and former Rapamune sales representative Mark ...